Stem Cell Therapy for Spinal Cord Injury
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications, such as anti-rheumatic drugs and systemic steroids, at least 3 months before enrolling. If you are currently on chronic immunosuppressive therapy or taking riluzole for ALS, you will not be eligible to participate.
What data supports the effectiveness of the treatment for spinal cord injury?
Research shows that using adipose-derived stem cells (cells taken from fat tissue) can help improve recovery in spinal cord injury. Studies in rats and some human cases have shown that these cells can aid in functional recovery, suggesting potential benefits for patients with spinal cord injuries.12345
Is stem cell therapy using adipose-derived mesenchymal stem cells safe for humans?
How is the treatment with Autologous Adipose Derived Mesenchymal Stem Cells different from other treatments for spinal cord injury?
This treatment is unique because it uses stem cells derived from a patient's own fat tissue, which are then infused back into the body to help repair spinal cord damage. Unlike other treatments, it focuses on using the body's own cells to promote healing and regeneration, offering a personalized approach to recovery.12347
Research Team
Mohamad Bydon, MD
Principal Investigator
Mayo Clinic
Eligibility Criteria
Adults aged 18+ with traumatic, non-penetrating spinal cord injuries (SCI) graded A or B at injury time, who've seen no significant improvement for a year. Participants must understand and commit to the study's requirements including home exercises and follow-ups. Women of childbearing age need a negative pregnancy test and must use contraception during the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive a single dose of autologous, adipose derived mesenchymal stem cells
Observation
Patients are observed over six months while attending physical and occupational therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Autologous Adipose Derived Mesenchymal Stem Cells
- Best Medical Management: Occupational and Physical Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor